Kodiak Sciences (NASDAQ:KOD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kodiak Sciences (NASDAQ:KOD – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Several other analysts have also issued reports on KOD. The Goldman Sachs Group initiated coverage on shares of Kodiak Sciences in a research report on Wednesday, September 30th. They set a “neutral” rating and a $103.00 price target for the company. Weiss Ratings lowered Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 6th. JPMorgan Chase & Co. increased their target price on Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Lifesci Capital raised their price target on Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a research report on Monday, September 28th. Finally, Jefferies Financial Group restated a “buy” rating and set a $112.00 price target on shares of Kodiak Sciences in a research report on Monday, September 28th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $109.00.

View Our Latest Stock Report on Kodiak Sciences

Kodiak Sciences Price Performance

Shares of NASDAQ KOD opened at $100.73 on Friday. The stock has a market capitalization of $6.33 billion, a P/E ratio of -24.69 and a beta of 2.02. Kodiak Sciences has a one year low of $18.15 and a one year high of $112.79. The firm’s 50 day simple moving average is $78.03 and its two-hundred day simple moving average is $46.12.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($1.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.01. As a group, equities analysts expect that Kodiak Sciences will post -3.97 earnings per share for the current fiscal year.

Insider Transactions at Kodiak Sciences

In other news, Director Bros. Advisors Lp Baker acquired 86,432 shares of the stock in a transaction dated Thursday, November 5th. The stock was purchased at an average cost of $98.51 per share, with a total value of $8,514,416.32. Following the completion of the purchase, the director owned 20,424,859 shares in the company, valued at approximately $2,012,052,860.09. The trade was a 0.42% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have acquired 2,188,845 shares of company stock valued at $181,326,862. 44.40% of the stock is owned by company insiders.

Institutional Trading of Kodiak Sciences

A number of institutional investors have recently modified their holdings of KOD. Soleus Capital Management L.P. purchased a new position in Kodiak Sciences during the 3rd quarter valued at about $27,204,000. Bellevue Group AG purchased a new stake in Kodiak Sciences in the 3rd quarter worth approximately $43,648,000. Cetera Investment Advisers purchased a new stake in Kodiak Sciences in the 3rd quarter worth approximately $231,000. Marshall Wace LLP bought a new stake in shares of Kodiak Sciences in the 3rd quarter worth approximately $9,584,000. Finally, Empowered Funds LLC bought a new stake in shares of Kodiak Sciences in the 3rd quarter worth approximately $746,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Kodiak Sciences Company Profile

(Get Free Report)

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.

Further Reading

Analyst Recommendations for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.